ClinicalTrials.gov
public full text
Public Domain
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease#28553
- Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease#136266
- Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease#900547
- Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus#854398
- Nonalcoholic Fatty Liver Disease as a Risk Marker for Incident Type 2 Diabetes Mellitus: A Systematic Review.#621024
Record · ID 136290
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive